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Abstract
The structural integrity of cerebral vessels is compromised during ageing. Abnormal amyloid (Ab) deposition in the
vasculature can accelerate age-related pathologies. The cerebrovascular response associated with ageing and microvascular
Ab deposition was defined using quantitative label-free shotgun proteomic analysis. Over 650 proteins were quantified in
vessel-enriched fractions from the brains of 3 and 9 month-old wild-type (WT) and Tg-SwDI mice. Sixty-five proteins were
significantly increased in older WT animals and included several basement membrane proteins (nidogen-1, basement
membrane-specific heparan sulfate proteoglycan core protein, laminin subunit gamma-1 precursor and collagen alpha-2(IV)
chain preproprotein). Twenty-four proteins were increased and twenty-one decreased in older Tg-SwDI mice. Of these,
increases in Apolipoprotein E (APOE) and high temperature requirement serine protease-1 (HTRA1) and decreases in
spliceosome and RNA-binding proteins were the most prominent. Only six shared proteins were altered in both 9-month
old WT and Tg-SwDI animals. The age-related proteomic response in the cerebrovasculature was distinctly different in the
presence of microvascular Ab deposition. Proteins found differentially expressed within the WT and Tg-SwDI animals give
greater insight to the mechanisms behind age-related cerebrovascular dysfunction and pathologies and may provide novel
therapeutic targets.
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Introduction
The structural integrity of the cerebrovasculature is altered
during ageing. These changes can be accelerated by vascular
pathologies, most notably cerebral amyloid angiopathy (CAA) [1],
[2], [3], [4], [5], [6], [7]. Ageing alone can lead to vessels
supplying deep white matter to become tortuous. Thickening of
the veins and venules is also commonly observed along with
increased thickening of the basement membrane [1]; [8]. A decline
in vascular density, specifically capillary loss, has been observed in
both the elderly and aged animal models [9], [10] along with
increases in arteriole and capillary diameter [11]. Many of these
same age-related pathologies are recapitulated in brains with
CAA, which is relatively common in the elderly population,
presenting in 10–40% of the non-demented individuals over the
age of 60 [12]. CAA can be categorized into two types identified
pathologically by the accumulation of Ab in leptomeningeal and
cortical vessels including capillaries (Type 1) or with the exception
of capillaries (Type 2) [13], [14]. CAA can lead to the loss of
smooth muscle cells and thickening of the vessel walls, which in
turn causes the blood vessel to become compromised, leading to
intracerebral hemorrhage [15].
The presence of Ab leads to very different protein changes that
are independent of age. This includes the modulation of proteins
that are involved in movement, aggregation and degradation of
Ab. APOE is a protein that is intimately involved in all of these
processes [16]: the expression of the APOE4 allele leads to a
propensity for increased Ab aggregation in sporadic AD [17] and
increased risk of Ab deposition in capillaries [13]. APOE plays a
direct role in Ab efflux across the blood brain barrier to circulating
plasma [18], [19], and its overexpression promotes Ab proteolysis
via enzymes such as neprilysin and insulin degrading enzyme [20].
Overexpression of neprilysin and insulin degrading enzyme
decrease Ab levels in transgenic amyloid precursor protein (APP)
mouse models and improve cognition [21].
The Tg-SwDI transgenic mouse model of amyloidosis expresses
human APP with three different mutations: the Swedish, Dutch
and Iowa mutations. The double Swedish mutation leads to
increased production and secretion of Ab [22]. The Dutch and
Iowa mutations, found in independent familial forms of CAA,
increase the propensity for Ab to accumulate in the vessels and are
associated with cortical hemorrhages [23]. The Tg-SwDI model
expresses the human APP gene at levels similar to endogenous
mouse APP levels [23], and yet develops a temporal accumulation
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of Ab. This latter accumulation of Ab is potentially attributed to
properties of the mutant Ab preventing normal clearance [24].
As the Ab accumulates over time, it associates closely with
microvessels, (seen in Type 1 CAA) and is primarily fibrillar in
nature [23], [25]. This microvascular deposition is closely
associated with an increased inflammatory response [23]. These
alterations observed in the Tg-SwDI, resulting from advancing age
and accumulating Ab, should be underpinned by changes in
various proteins, including those associated with the neurovascular
unit and the blood brain barrier [7], [26], [27], [28], [29] yet the
scope of these changes are not fully understood.
To better understand how cerebral vessels globally respond to
both age and accumulating Ab, we have used a quantitative label-
free proteomics approach to investigate the proteomic signatures
of vessel-enriched fractions from the brains of WT and Tg-SwDI
mice at 3 and 9 months of age. Our vascular-focused approach has
revealed distinctly different protein expression patterns as a result
of age in the presence of microvascular Ab accumulation.
Materials and Methods
Ethics Statement
All procedures were authorized under the Home Office
approved project license number 60/3722. This license was
approved by the University of Edinburgh’s Ethical Review
Committee and the Home Office and adhered to regulations
specified in the Animals (Scientific Procedures) Act (1986).
Animals
Tg-SwDI mice were obtained from Jackson Laboratories (Bar
Harbour, MA). These mice were generated and previously
described [23] on a C57Bl/6J background. Homozygous Tg-
SwDI mice were bred and maintained. C57Bl/6J (WT) mice were
obtained from Jackson laboratories through their UK distributor
Charles River.
Vessel Enrichment
Vessels were enriched using a protocol based on 2 sources [30],
[31]. Hemibrains were homogenized in 1 mL of ice-cold PBS
using a loose fit dounce homogenizer using 15 strokes. Homog-
enates were transferred to a 15 mL falcon tube and centrifuged for
10 minutes at 2506g. The pellet was re-suspended in 17.5% Ficoll
solution (Sigma) and centrifuged for 25 minutes at 3,2006g to
collect the pellet (vessel containing S1 fraction), which was retained
on ice. The supernatant was centrifuged again for 25 minutes at
32006g to collect a second pellet and the pellets from both spins
were combined in 1 mL of 1% BSA-PBS and re-suspended. The
suspension was centrifuged for 10 minutes at 20006g. The pellet
was subsequently washed in 1 mL of ice-cold PBS before being
flash-frozen on dry ice and later stored at 270uC until further
processing.
Immunoblots
S1 fractions obtained from hemibrains of 3 month-old WT mice
(n = 3) for vessel enrichment confirmation were homogenized in a
lysis buffer of 9 M Urea/4% CHAPS with Complete Protease
Inhibitor Cocktail (Roche, Manheim, Germany). Protein levels
were determined using a Pierce BCA protein assay kit (Thermo
Scientific, Cramlington, Northumberland, UK). Proteins were
separated by SDS–PAGE and transferred onto nitrocellulose
membranes.
S1 fractions obtained from hemibrains of 3, 12 and 17 month-
old Tg-SwDI mice (n = 4/group) for APOE and HTRA1
confirmation were homogenized in a sucrose buffer with Complete
Protease Inhibitor Cocktail (Roche, Manheim, Germany). Protein
levels were determined as above and proteins were separated by
SDS–PAGE and transferred onto PVDF membranes (Bio-Rad,
Germany).
Immunoblotting was performed using the Odyssey Infrared
Imaging System (LiCor Biosciences, Lincoln, NE, USA). Mem-
branes were blocked in Odyssey blocking buffer (diluted 1:1 with
phosphate-buffered saline) and washed in phosphate-buffered
saline–TweenH (phosphate-buffered saline with 0.1% Tween).
Primary antibodies were detected using fluorescently labelled
secondary antibodies (LiCor Biosciences). Proteins were visualized
by scanning antibody-labelled blots in the Odyssey Imager under
the appropriate channel. Antibodies for immunoblotting were as
follows: Platelet endothelial cell adhesion molecule (PECAM),
smooth muscle actin (SMA), glial fibrillary acid protein (GFAP)
(AbCam, Cambridge, UK), Occludin (Invitrogen, Camarillo, CA,
USA).
Cerebral Vessel Ab Levels
Total Ab was extracted from independent S1 fractions taken
from independent cohorts of 3, 12 and 17 month-old Tg-SwDI
mice (n = 4/group) using a homogenisation buffer of the following
constituents: 5 M guanidine and 50 mM Tris/HCL and mixed for
3–4 hours at RT and later stored at 220uC. The solution was
diluted 1:10 in ice-cold reaction buffer of the following constitu-
ents: 0.2 g/L KCL, 0.2 g/L KH2PO4, 8 g/L NaCl, 1.15 g/L
Na2HPO4, 5% BSA, 0.03% Tween 20 and 1X protease inhibitor
cocktail (Calbiochem). The solution was centrifuged at 16,0006g
for 20 minutes at 4uC. Protein levels were quantified with Pierce
BCA Protein Assay Kit (Thermo Scientific). Ab1-40 levels were
measured using the Invitrogen Human Ultrasensitive ELISA kit
(Life Technologies, Paisley, UK) following the manufacturer’s
instructions.
LC-MS Analysis of Vessel-enriched Fractions
All chemicals were purchased from Sigma-Aldrich (UK) unless
otherwise stated. Acetonitrile and water for LC-MS/MS and
sample preparation were HPLC quality (Fisher, UK). Formic acid
was Suprapure 98–100% (Merck, Darmstadt, Germany) and
trifluoroacetic acid was 99% purity sequencing grade. Trypsin and
Lys-C (modified, sequencing grade) were purchased from Roche
Diagnostics (West Sussex, UK). All HPLC-MS connector fittings
were from Upchurch Scientific or Valco (Hichrom and RESTEK,
UK).
100 mg of protein extract from the vessel-enriched fractions
from 3 and 9 month-old, Tg-SwDI and WT mice (n = 7–8/group)
was re-suspended in 45 mL of 8 M urea, 2.5 mL of 200 mM DTT
and 5 mL of 1 M ammonium bicarbonate. The samples were
reduced at room temperature for 30 minutes, and then 2.5 mL of
500 mM iodoacetamide was added. 0.5 mg of Lys-C was added
and digested overnight in 6 M urea followed by dilution to 2 M
urea and overnight digestion with 2 mg of trypsin.
Capillary-HPLC –MSMS data were collected on an online
system consisting of a micropump (1200 binary HPLC system,
Agilent, Edinburgh, UK) coupled to a hybrid LTQ-Orbitrap XL
instrument (Thermo-Fisher, Loughborough, UK). HPLC-MS
methods have been described previously [32]. Peptides were
reconstituted in 10 mL of loading buffer before injection and 8 mL
was loaded. The peptide mixture was separated using a 140 min
gradient form 0% to 100% Buffer B (Buffer A: 2.5% acetonitrile
0.1% formic acid and buffer B 90% acetonitrile, 0.025%
trifluoracetic acid, and 0.1% formic acid).
The mass spectrometer was operated in ‘data-dependent mode’,
with a single MS scan (400 to 2,000 m/z) in FT mode 60 K
Cerebrovascular Proteomes of WT and Tg-SwDI Mice
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resolution followed by 5 MS/MS scans in the linear ion trap on
the most abundant ions and dynamic excluded for 120 seconds.
Protein Identification and Quantification
Conversions from RAW to MGF files were performed as
described previously [32], [33]. MS/MS data were searched using
MASCOT Versions 2.3 (Matrix Science Ltd., London, UK)
against a mouse plus contaminant database downloaded from
NCBI with 30,061 sequences (From 12 January 2011) and
amended with human APP with the Swedish, Dutch and Iowa
mutations due to the transgenic nature of the mouse model.
Variable methionine oxidation, STY phosphorylation, protein N-
terminal acetylation, and fixed cysteine carbamidomethylation
were used in all searches. Precursor mass tolerance was set to 7
ppm and MS/MS tolerance to 0.4 amu. LC-MS label-free protein
Figure 1. Vessel fractions are enriched in vascular-associated proteins. S1 fractions were enriched in proteins associated with various
cellular compartments of cerebral vessels as demonstrated by increased levels of Occludin, PECAM, SMA and GFAP. a-tubulin showed similar
expression across all blots. (A–D) Levels of selected proteins (relative to respective a-tubulin levels) were all significantly enriched in the S1 fraction
compared to whole brain samples (n = 3/gp; p,0.001; t-test). WB=whole brain fraction; S1 = vessel-enriched fraction.
doi:10.1371/journal.pone.0089970.g001
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abundance data derived from MS-speak data were calculated
using Progenesis software.
Regarding the label free quantification, the total number of
Features (i.e. intensity signal at a given retention time and m/z)
was reduced to MS/MS peaks with charge of 2, 3, or 4+ and we
only kept the five most intense MS/MS spectra per ‘‘Feature’’.
The subset of multi-charged ions (2+, 3+ and 4+) was extracted
from each LC-MS run and the ions intensities summed for
normalization. Protein quantification was performed as follows; for
a specific protein, the associated unique peptide ions were summed
to generate an abundance value. The final list of measured protein
abundances were transformed using an ArcSinH function (as the
method of detection can generate a significant amount of near
zero measurement for which a log transform is not ideal). The
within group means were calculated to determine the fold change
and the transformed data was then used to calculate the p-values.
Differentially expressed proteins were considered most meaningful
under the following conditions: Only proteins detected by two or
more peptides and p,0.01 associated with the protein change.
Gene Ontology Analysis
Proteins found to be significantly different at p,0.01 within the
WT and Tg-SwDI cohorts were uploaded to WebGestalt Gene Set
Analysis Toolkit version 2 (http://bioinfo.vanderbilt.edu/
webgestalt, Vanderbilt University) for enrichment analysis based
on gene ontology [34], [35]. Cut-off criteria included a p,0.01
adjusted with hypergeometric statistical analysis using Benjamini
& Hochberg multiple test adjustment with a minimum molecule
cut-off of 2.
KEGG Pathway Analysis
For pathway analysis, the p-value threshold was set at p,0.05 to
strengthen network analysis. Proteins found to be significantly
different at p,0.05 within the WT and Tg-SwDI cohorts were
uploaded to WebGestalt Gene Set Analysis Toolkit version 2 for
enrichment analysis based on the Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathway maps using the same criteria
above.
Immunohistochemistry
At 3 and 9 months of age, Tg-SwDI and WT mice were deeply
anaesthetised with 5% isoflurane and transcardially perfused with
20 ml 0.9% heparinized phosphate buffered saline followed by
20 ml of 4% paraformaldehyde in 0.1% phosphate buffer. Brains
were removed and post-fixed in 4% PFA over-night and paraffin
embedded.
Coronal tissue sections from each respective cohort were
deparaffinized using standard procedures. Briefly, sections were
incubated at 60uC for 30 minutes, followed by further dewaxing in
xylene. Slides were then placed sequentially in 100%, 90% and
finally 70% alcohol before being rinsed in running water. Sections
were processed for antigen retrieval by being incubated in 10 mM
citric acid for 10 minutes at 100uC in a pressurized retrieval
machine. For APOE immunostaining sections were blocked with
normal donkey serum and incubated sequentially with goat
polyclonal APOE (Calbiochem) along with mouse monoclonal
b-dystroglycan (Leica Microsystems) followed by Alexa Flour488H-
labelled mouse monoclonal 6E10 (Covance) overnight at 4uC.
APOE and b-dystroglycan were visualized with Cy3-labelled and
Cy5-labelled secondary antibodies respectively. For HTRA1
immunostaining sections were blocked with normal goat serum
and incubated sequentially with rabbit polyclonal HTRA1
(Abcam) along with mouse monoclonal b-dystroglycan (Leica
Microsystems), followed by Alexa Flour488H-labelled mouse
monoclonal 6E10 (Covance) overnight at 4uC. HTRA1 and b-
dystroglycan were visualized with Alexa Flour 546 and 646
respectively. Sections were analyzed using a laser scanning
confocal microscope (Leica SP5). All images were acquired with
a 406oil-immersion objective within the thalamus. Image analysis
was carried out using NIH image J 1.47d software.
Statistical Analysis
Data were analysed using student’s t-test or one-way ANOVA
where experimental design exceeded 2 comparisons. For the LC-
MS data significance was set at p,0.01. For all other analyses
significance was set at p,0.05.
Figure 2. Proteomic design and workflow. (A) Vessel enriched fractions were collected from 3 month-old and 9 month-old WT and 3 month-old
and 9 month-old Tg-SwDI mice for proteomic analysis. (B) Over 1,000 proteins were identified, with over 70% being identified by more than two
peptides. 654 proteins were quantified by at least two peptides and were statistically analysed using Progenesis software. 65 proteins were found to
be up-regulated in the WT animals. 45 proteins were found to be up- and down-regulated (21 and 24 respectively) in the Tg-SwDI animals. Those
proteins that were found to be significantly different within the respective cohorts were analysed further with WebGestalt web-based software.
doi:10.1371/journal.pone.0089970.g002
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Table 1. Proteins significantly increased in older wild-type mice (9 months) relative to young wild-type mice (3 months).
Description - 9 month Wt vs 3 month WT Accession p-value Fold Change
basement membrane-specific heparan sulfate proteoglycan core protein gi_183979966 0.000007 2.68
myelin-associated oligodendrocyte basic protein isoform b gi_86355503 0.00001 2.35
collagen alpha-2(IV) chain preproprotein gi_226437587 0.00003 2.83
tubulointerstitial nephritis antigen-like precursor gi_270132817 0.00004 2.88
laminin subunit gamma-1 precursor gi_153791270 0.0001 2.55
laminin subunit beta-2 precursor gi_31982223 0.0002 2.42
glycerol-3-phosphate dehydrogenase 1-like protein gi_257467604 0.0003 1.82
histone H1.4 gi_13430890 0.0003 2.31
nidogen-1 precursor gi_171543883 0.0003 2.12
agrin gi_42490751 0.0003 2.00
myelin-oligodendrocyte glycoprotein gi_113199771 0.0004 1.90
histone H2A type 2-A gi_20799907 0.0006 1.92
claudin-11 gi_6679186 0.001 1.74
synaptic vesicle membrane protein VAT-1 homolog gi_33859662 0.001 1.59
myelin basic protein isoform 1 gi_69885032 0.001 1.48
moesin gi_70778915 0.001 1.61
fibrinogen gamma chain precursor gi_19527078 0.001 8.77
3-ketoacyl-CoA thiolase, mitochondrial gi_29126205 0.001 1.51
receptor expression-enhancing protein 5 gi_161016826 0.001 1.48
vimentin gi_31982755 0.001 1.66
myelin proteolipid protein gi_23956058 0.002 1.83
cysteine and glycine-rich protein 1 gi_6681069 0.002 1.56
solute carrier family 2, facilitated glucose transporter member 1 gi_165377226 0.002 1.51
nidogen-2 precursor gi_84370361 0.002 2.23
D-3-phosphoglycerate dehydrogenase gi_52353955 0.002 1.55
coronin-2B gi_148528987 0.002 1.81
peroxiredoxin-6 gi_6671549 0.003 1.33
glycerol-3-phosphate dehydrogenase, mitochondrial precursor gi_224922803 0.003 1.57
peptidyl-prolyl cis-trans isomerase FKBP1A gi_6679803 0.003 1.63
voltage-dependent anion-selective channel protein 3 isoform 2 gi_6755967 0.003 1.54
microtubule-associated protein 1A isoform 1 gi_124244033 0.003 1.61
voltage-dependent anion-selective channel protein 2 gi_6755965 0.003 1.61
tubulin beta-2C chain gi_22165384 0.003 1.63
myosin-11 isoform 1 gi_241982716 0.003 2.12
CD9 antigen gi_6680894 0.003 2.18
succinyl-CoA ligase [GDP-forming] subunit alpha, mitochondrial precursor gi_255958286 0.003 1.94
multidrug resistance protein 3 gi_153791547 0.003 1.48
acyl-CoA-binding protein isoform 2 gi_6681137 0.004 1.72
mesotrypsin gi_6755891 0.004 1.80
alpha-internexin gi_148539957 0.004 1.49
contactin-associated protein 1 precursor gi_116063560 0.004 1.52
dihydropteridine reductase gi_21312520 0.004 1.56
histone H1.0 gi_31560697 0.004 1.83
aldehyde dehydrogenase, mitochondrial precursor gi_6753036 0.004 1.56
histone H1.2 gi_9845257 0.005 1.78
band 3 anion transport protein gi_6755560 0.005 2.44
profilin-2 gi_9506971 0.005 1.51
peroxiredoxin-2 gi_148747558 0.006 1.45
guanine nucleotide-binding protein G(i) subunit alpha-2 gi_41054806 0.006 1.41
electron transfer flavoprotein subunit beta gi_38142460 0.006 1.48
Cerebrovascular Proteomes of WT and Tg-SwDI Mice
PLOS ONE | www.plosone.org 5 February 2014 | Volume 9 | Issue 2 | e89970
Results
Vessel Enrichment: S1 Fractions are Enriched in Vessel-
associated Proteins
Vascular enrichment was conducted using modifications of
previously published protocols [30], [31]. To verify that there was
vascular enrichment, S1 fractions from 3 month-old WT mice
(n = 3) were compared to whole brain (WB) fractions and the levels
of four cerebrovascular-associated proteins were measured. These
proteins were selected due to their critical importance in multiple
cellular compartments of cerebral vessels; a marker of vascular
smooth muscle (SMA); a marker of endothelial tight junctions
(occludin), an endothelial marker (PECAM) and a marker of
astrocytes (GFAP). The data demonstrated that S1 fractions were
enriched by 3–12 fold [Occludin (7 fold), PECAM (11 fold), SMA
(12 fold), GFAP (3 fold)] (Figure 1).
Temporal Increase in Vascular Ab1-40
The levels of Ab1-40 were measured since this is the most
prominent Ab species in the cerebrovasculature of Tg-SwDI
animals [23], whose negative charge in its mutant form contributes
to its increased pathogenicity [36], [37] and its reduced clearance
due to its lower affinity to LRP [38]. As predicted, the mean levels
of Ab1-40 (pg/mg of total tissue 6 S.E.M) were significantly
higher in vessel fractions from the 12 and 17 month-old Tg-SwDI
mice (220.866.29 and 226619.22 respectively) compared to the 3
month-old mice (10.72610.72; p,0.0001; one-way ANOVA).
Proteomic Analysis of Vessel Fractions
1024 proteins were identified within the S1 fractions from
young and older WT and Tg-SwDI mice. 654 were quantified by
at least 2 peptides across all groups (a list of all proteins quantified
by 2 peptides can be found in Table S1). The proteomic workflow
along with a summary of results is presented (Figure 2).
65 proteins were significantly different (p,0.01) between the 3
month-old WT and 9 month-old WT mice. All of these proteins
were up-regulated (Table 1).
45 proteins were found to be significantly different (p,0.01)
between the 3 month-old Tg-SwDI and 9 month-old Tg-SwDI
mice. 24 proteins were up-regulated and 21 were down-regulated
(Table 2).
Of those proteins that were significantly different within the
cohorts, only 6 proteins overlapped between the WT and Tg-
SwDI cohorts. This indicates differential responses to age within
the WT and Tg-SwDI cohorts (Tables 1&2).
KEGG Pathway Analysis
Proteins found to be significantly different (p,0.05) between the
3 month-old and 9 month-old WT animals (178 proteins) along
with those significantly different (p,0.05) between the 3 month-
old Tg-SwDI and 9 month-old Tg-SwDI animals (154 proteins)
were uploaded to the WebGestalt Gene Set Analysis Toolkit
version 2 for cohort-specific KEGG pathway analysis.
KEGG pathway analysis revealed similar pathways being
represented within the WT and Tg-SwDI cohorts. The top
biological processes for both cohorts included: metabolic pathways
and several neurodegenerative related pathways: Alzheimer’s disease,
Parkinson’s disease and Huntington disease (See figure 3). Both 9
month-old WT and 9 month-old Tg-SwDI animals showed up-
regulation of proteins represented by the oxidative phosphorylation
category as well as the gap junction category. Closer inspection of the
proteins contained within certain categories reveal a divergence in
the proteins being modulated within the respective cohorts, with
only about a third of the proteins being shared within the metabolic
pathways and oxidative phosphorylation categories. Other categories
(e.g. gap junction) show much more convergence.
Age Effects on the WT Vascular Proteome
In WT animals, age led to a marked up-regulation of proteins
associated with the basement membrane based on gene ontology
(cellular compartment; Figure S1), particularly nidogen-1, base-
ment membrane-specific heparan sulfate proteoglycan core
protein, laminin subunit gamma-1 precursor and collagen alpha-
2(IV) chain preproprotein (Figure 4).
Table 1. Cont.
Description - 9 month Wt vs 3 month WT Accession p-value Fold Change
myelin-associated glycoprotein gi_6754614 0.006 1.50
carbonic anhydrase 2 gi_157951596 0.006 1.74
choline transporter-like protein 1 isoform A gi_227499980 0.007 1.83
60S ribosomal protein L13 gi_33186863 0.007 2.12
hemoglobin subunit beta-1 gi_31982300 0.007 3.97
potassium voltage-gated channel subfamily A member 2 gi_157012015 0.008 1.48
cytochrome c, somatic gi_6681095 0.009 2.16
cytochrome b-c1 complex subunit 8 gi_21539585 0.009 1.41
microtubule-associated protein 6 isoform 1 gi_113204613 0.009 1.54
prohibitin-2 gi_126723336 0.009 1.38
plectin isoform 1d gi_254675251 0.009 1.43
hemoglobin alpha, adult chain 2 gi_145301549 0.009 4.09
tubulin beta-5 chain gi_7106439 0.010 1.53
MOSC domain-containing protein 2, mitochondrial precursor gi_19526848 0.010 1.52
tubulin beta-4 chain gi_31981939 0.010 1.56
doi:10.1371/journal.pone.0089970.t001
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Table 2. Proteins significantly increased (positive fold change) and decreased (negative fold change) in older Tg-SwDI mice (9
months) relative to young Tg-SwDI mice (3 months).
Description - 9 month Tg-SwDI vs 3 month Tg-SwDI Accession p-value Fold Change
apolipoprotein E precursor gi_163644329 0.000003 3.86
serine protease HTRA1 precursor gi_229093139 0.000003 6.26
heterogeneous nuclear ribonucleoproteins A2/B1 isoform 2 gi_32880197 0.00003 23.96
heterogeneous nuclear ribonucleoprotein A1 isoform a gi_6754220 0.0001 22.96
heterogeneous nuclear ribonucleoprotein U-like protein 2 gi_124487099 0.0001 23.82
heterogeneous nuclear ribonucleoprotein D0 isoform a gi_116256512 0.0002 23.49
heterogeneous nuclear ribonucleoprotein K gi_13384620 0.0003 23.09
heterogeneous nuclear ribonucleoproteins C1/C2 isoform 1 gi_8393544 0.0003 22.95
heterogeneous nuclear ribonucleoprotein L gi_183980004 0.0003 22.87
CD9 antigen gi_6680894 0.001 2.44
myelin-associated oligodendrocyte basic protein isoform b gi_86355503 0.001 2.24
alpha-crystallin B chain gi_6753530 0.001 2.68
protein kinase C & casein kinase substrate in neurons protein 1 isoform 1 gi_6754974 0.001 2.23
heterogeneous nuclear ribonucleoprotein H gi_10946928 0.001 22.84
CUGBP Elav-like family member 2 isoform 6 gi_124286791 0.001 23.25
alcohol dehydrogenase [NADP+] gi_10946870 0.001 1.84
TAR DNA-binding protein 43 isoform 1 gi_21704096 0.001 22.44
myelin expression factor 2 isoform 1 gi_244790087 0.001 22.57
gap junction alpha-1 protein gi_6753992 0.002 2.19
V-type proton ATPase subunit G 2 gi_12963559 0.002 2.06
serine/arginine-rich splicing factor 7 isoform 1 gi_22122585 0.002 21.67
lupus La protein homolog gi_6678143 0.002 22.32
intercellular adhesion molecule 5 precursor gi_159110562 0.002 2.47
poly(rC)-binding protein 2 isoform 1 gi_157041229 0.003 23.05
matrin-3 gi_25141233 0.003 22.08
heterogeneous nuclear ribonucleoprotein U gi_160333923 0.003 22.13
profilin-1 gi_6755040 0.004 2.20
polypyrimidine tract-binding protein 2 gi_9507003 0.004 23.13
mitochondrial glutamate carrier 2 gi_124486670 0.004 1.96
protein bassoon gi_124487407 0.005 1.90
glial fibrillary acidic protein isoform 2 gi_84000448 0.005 1.85
clathrin light chain A isoform a gi_122939192 0.005 1.66
D-3-phosphoglycerate dehydrogenase gi_52353955 0.005 1.74
heterogeneous nuclear ribonucleoprotein H2 gi_9845253 0.006 22.51
peroxiredoxin-6 gi_6671549 0.006 1.42
vesicle-associated membrane protein-associated protein A gi_94721328 0.007 1.71
vesicle-associated membrane protein-associated protein B gi_31543940 0.007 2.04
KH domain-contain., RNA-binding, signal transduction-assoc. protein 1 gi_110626031 0.007 23.80
proline-rich transmembrane protein 2 gi_156523248 0.008 1.74
heterogeneous nuclear ribonucleoprotein G gi_83699420 0.008 21.80
heterogeneous nuclear ribonucleoprotein R gi_33859724 0.008 22.22
3-ketoacyl-CoA thiolase, mitochondrial gi_29126205 0.009 1.74
heterogeneous nuclear ribonucleoprotein A/B isoform 2 gi_6754222 0.009 22.32
PREDICTED: ras GTPase-activating protein SynGAP gi_309263645 0.009 1.80
myc box-dependent-interacting protein 1 isoform 1 gi_6753050 0.010 1.57
potassium voltage-gated channel subfamily A member 2 gi_157012015 0.010 1.99
doi:10.1371/journal.pone.0089970.t002
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Age also led to the up-regulation of several white matter-
associated proteins in WT animals (and to a lesser extent in Tg-
SwDI animals, including myelin-associated oligodendrocyte basic
protein, myelin-oligodendrocyte glycoprotein, myelin proteolipid
protein, myelin associated glycoprotein, contactin-associated
protein-1 precursor and myelin basic protein isoform 1 (Figure S2).
Age Effects on the Tg-SwDI Vascular Proteome
HTRA1 and APOE were markedly increased in the 9 month-
old as compared to 3 month-old Tg-SwDI animals (*p,0.0001)
(Figure 5A, B). There were no differences detected between 3
month and 9 month-old WT mice. Serine protease HTRA1 was
the most up-regulated protein within the Tg cohort (fold
change= 6.26) followed by APOE (fold change= 3. 86). To
confirm that these alterations in APOE and HTRA1 were a
robust finding and increasing with age, the levels of these proteins
were measured by Western blot in separate cohorts to those in
which LC-MS was conducted at ages 3, 12 and 17 months (Tg-
SwDI n=4/grp). Immunoblot analysis confirmed a age-depen-
dent increase in HTRA1 (*p,0.05; **p,0.01) (Figure 5C) and in
APOE levels (p = 0.096) in vascular fractions (Figure 5D). How-
ever, there was no correlation between Ab1-40 levels and HTRA1
or APOE levels in the same vessel fractions (Figure 5E, F).
Age led to the extensive down-regulation of several proteins
associated with the spliceosome (note figure 3) and RNA processing
in the Tg-SwDI animals based on gene ontology (biological
Figure 3. KEGG pathway analysis suggests similar patterns of expression. The Kyoto Encyclopedia of Gene and Genomes (KEGG) pathway
analysis resulted in similar lists of modulated pathways representing proteins found to be significantly within the different cohorts (p,0.05; t-test).
Venn diagrams show divergences in the proteins that make up those pathways. Both WT and Tg-SwDI animals show changes in (A) metabolic
pathways, specifically (B) oxidative phosphorylation, though only a third of the modulated proteins represented by the KEGG pathways are shared. The
(C) gap junction pathway share many more proteins between WT and Tg-SwDI cohorts.
doi:10.1371/journal.pone.0089970.g003
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process; Figure S3). These include several members of the
heterogeneous nuclear ribonucleoprotein family of proteins
(Figure 6).
APOE Localizes to Cerebral Vessels and Accumulated Ab
Tissue from independent cohorts of 3 month-old WT, 9 month-
old WT, 3 month-old Tg-SwDI and 9 month-old Tg-SwDI mice
were immunolabelled with antibodies to b-dystroglycan, Ab and
APOE. APOE immunolabelling was mostly observed in 9 month-
old Tg-SwDI animals (Figure 7A–D). APOE co-localized to both
accumulated Ab and cerebral vessels, particularly those vessels
proximate to Ab deposits within the thalamus.
HTRA1 is Located Proximately to Ab-laden Vessels in the
Thalamus
Tissue from independent cohorts of 3 month-old WT, 9 month-
old WT, 3 month-old Tg-SwDI and 9 month-old Tg-SwDI mice
(as above) were immunolabelled with antibodies to b-dystroglycan,
Ab and HTRA1. HTRA1 immunolabelling was mostly observed
in 9 month-old WT and Tg-SwDI sections and appeared to be
expressed cytoplasmically (Figure8 A–D). Only in 9 month-old Tg-
SwDI mice was HTRA1 found to be located proximately to Ab-
laden vessels (Figure 8E–J) within the thalamus and appeared
extracellular.
Discussion
Brain ageing leads to alterations in the protein components of
the cerebrovascular milieu, which can lead to changes in vascular
integrity and decreased functioning of the NVU and the BBB [6],
[7], [8]. Pathological insults such as CAA can accelerate these
changes, [39] [40], [41]. Quantitative proteomics allowed an in-
depth and global investigation of the protein profiles of the
cerebrovascular milieu of WT and Tg-SwDI animals at distinctly
different ages. We were able to identify proteins that might be
contributing to these age-dependent changes by looking specifi-
cally at vascular enriched fractions. These vascular fractions were
enriched in proteins associated with cerebral vessels (PECAM,
occludin, SMA, GFAP, ABCB1A, nidogen, claudin 11 and AQP4,
Table S1) using techniques similar to those used under physiolog-
ical conditions [31] and in genetically altered models with cerebral
haemorrhage propensity [42].
The number of proteins that were changed between the 3 and 9
month-old WT animals (n = 65) and the 3 and 9 month-old Tg-
SwDI animals (n = 45) were substantial in number, yet the protein
lists generated from the two cohorts had very little overlap,
suggesting that age affected the vascular proteomic profile of the
WT and Tg-SwDI animals in very different ways. We hypothe-
sized that age would have a differential effect on the cerebrovas-
cular proteome in the presence of microvascular Ab.
KEGG pathway analysis suggested that many of the pathways
enriched by significantly modulated proteins were in fact very
similar between the WT and Tg-SwDI cohorts. Further scrutiny of
these revealed minimal overlap of the proteins the categorical
terms represented, again confirming differential regulation of
protein expression within the two cohorts. Examples of this include
two of the most significantly enriched pathways for both WT and
Tg-SwDI cohorts: metabolic pathways and oxidative phosphorylation
indicating changes in multiple mitochondrial proteins. Only 30%
of those mitochondrial proteins that were found to be differentially
modulated with the cohorts overlapped.
Despite the lack of overlap, modulations of mitochondrial
proteins are of great importance to age-related vascular changes.
The cerebrovasculature endothelium is highly enriched in
Figure 4. Age effects on the WT vascular proteome. 4 selected basement membrane proteins were significantly up-regulated in 9 month-old
WT animals by at least 2 fold (Mean abundance 6 S.E.M.; ***p,0.001; t-test). No significant difference was observed in the Tg-SwDI animals for these
same proteins.
doi:10.1371/journal.pone.0089970.g004
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mitochondria due to the high energy demands required for
neurovascular coupling [43] as well as for the multitude of ATP-
dependent transporters at the BBB required for bidirectional
transport of molecules to the brain [6]. Mitochondrial dysfunction
is associated with both brain ageing and accumulating Ab and is
closely linked to increases in oxidative stress [44], [45], [46], [47].
Such modulations like those observed in the older WT and Tg-
SwDI animals suggest that the age does lead to changes in the
expression of certain mitochondrial proteins, especially those that
make up the electron transport chain.
Basement membrane thickening due to increases in proteins
such as collagen has been observed with age and AD [8], [48],
[49]. Of the 65 proteins up-regulated in 9 month-old WT animals,
10% are intimately linked to the basement membrane (nidogen-1,
nidogen-2, laminin subunit gamma-1 precursor, collagen alpha-
2(1V) chain preproprotein, laminin subunit beta-2 precursor,
Figure 5. Age effects on the Tg-SwDI vascular proteome. (A) Serine protease HTRA1 and (B) Apolipoprotein E were significantly different
between 3 month-old and 9 month-old Tg-SwDI animals (Mean abundance 6 S.E.M; ***p,0.0001; t-test), whereas no differences were detected
between the WT animals of the same age. Serine protease HTRA1 was the most up-regulated protein within the Tg cohort (fold change= 6.26)
followed by APOE (fold change= 3. 86). In separate cohorts to those used for LC-MS, immunoblot analysis of 3, 12 and 17 month-old Tg-SwDI animals
(n = 4/grp, representative blots shown below respective cohort) confirmed an age-dependent increase in (C) HTRA1 (Mean relative intensity 6 S.E.M;
*p,0.05; **p,0.01, one-way ANOVA, Bonferroni post-test) and in (D) APOE levels (Mean relative intensity 6 S.E.M; p = 0.097, one-way ANOVA). No
correlation could be made between Ab1-40 levels and (E) HTRA1 or (F) APOE levels in the same vessel fractions.
doi:10.1371/journal.pone.0089970.g005
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basement membrane specific heparin sulphate proteoglycan core
protein, agrin). At 9 months of age the mice are not aged by
convention, yet there is still evidence of a temporal increase in key
basement membrane proteins over a 6 month period. This
increase is not seen in the Tg-SwDI mice. Instead, comparison of
these protein levels across all 4 groups indicates the abundance of
these same proteins is typically greater in 3 month-old Tg-SwDI
animals as compared to 3 month-old WT animals (Figure 4) and
remained stable as the animals aged and Ab accumulated.
In the present study, alterations in protein signatures were
studied in vascular-enriched fractions which allows for the
identification of proteins in cellular compartments in close
association with the vasculature. Notably white matter-associated
proteins were identified and found to be altered in older WT and
Figure 6. Age effects on the Tg-SwDI vascular proteome. Multiple heterogeneous nuclear ribonucleoproteins were down-regulated in 9
month-old Tg-SwDI animals (Mean abundance 6 S.E.M; ***p,.001; **p,0.01; t-test) compared to younger animals. No significant difference was
observed in the WT cohort.
doi:10.1371/journal.pone.0089970.g006
Cerebrovascular Proteomes of WT and Tg-SwDI Mice
PLOS ONE | www.plosone.org 11 February 2014 | Volume 9 | Issue 2 | e89970
Figure 7. Increases in APOE levels are specific to 9 mos Tg-SwDI mice. Tissue sections representative of independent 3 and 9 month-old WT
(A&B) and 3 and 9 month-old Tg-SwDI (C&D) animals were triple-labelled with APOE (red), 6E10 (green) and b-dystroglycan (magenta) and analysed
with a laser scanning confocal microscope within the thalamus (4006). Immunohistochemical analysis of the four different cohorts show APOE and
Ab present only in the (D) 9 month Tg-SwDI animals. APOE co-localized (shown in white) with both (E) 6E10-labelled Ab and (F) b-dystroglycan-
labelled cerebral vessels. (G) Ab is closely associated with cerebral vessels.
doi:10.1371/journal.pone.0089970.g007
Figure 8. HTRA is located proximately to Ab-laden vessels in the thalamus of 9 mos Tg-SwDI mice. Tissue sections representative of
independent 3 and 9 month-old WT (A&B) and 3 and 9 month-old Tg-SwDI (C&D) animals were triple-labelled with HTRA1 (red), 6E10 (green) and b-
dystroglycan (magenta) and analysed with a laser scanning confocal microscope (4006). Immunohistochemical analysis of the four different cohorts
show HTRA1 closely associated with Ab-laden vessels [white arrow, (D)] within the thalamus of 9 month-old Tg-SwDI mice (E–J) and appeared
extracellular.
doi:10.1371/journal.pone.0089970.g008
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TgSWDI mice as compared to the respective younger cohorts.
This included the significant up-regulation of myelin-oligodendro-
cyte glycoprotein, myelin proteolipid protein, myelin associated
glycoprotein, contactin-associated protein-1 precursor and myelin
basic protein isoform 1 in older WT mice. Only myelin-associated
oligodendrocyte basic protein, the third most prevalent protein in
myelin [50] was found to be significantly up-regulated in both
older WT and Tg-SwDI mice. Furthermore, in older Tg-SwDI
mice, a down-regulation in myelin expression factor 2 isoform 1, a
suppressor of MBP expression [51] was observed, which was not
seen in the older WT mice. This is an indication that these white
matter-associated proteins are differentially altered in older WT
mice as compared to those found to be altered in the older
TgSWDI mice.
The integrity of white matter has been reported to be
compromised in ageing and in models of amyloidosis [52], [53],
[54]. Whilst studies have previously shown alterations in myelin
proteins with ageing the results are conflicting with some studies
showing a reduction in specific proteins like myelin basic protein
[55] and others finding the up-regulation or complete lack of
change in proteins such as 29,39 cyclic nucleotide 39-phosphodi-
esterase or proteolipid protein respectively [56]. Furthermore the
spatial organisation of proteins on myelinated axons, such as those
found within paranodal regions, may be altered and can respond
dynamically to various challenges including cerebral hypoperfu-
sion and amyloid plaques [57], [58], [59]. In the present study we
found a marked up-regulation of a greater number of myelin-
associated proteins in older WT mice compared to TgSWDI.
These differences are likely due to whn and how these changes are
measured and suggest complex regulatory control of myelin
protein expression. One of the most up-regulated proteins within
the 9 month-old Tg-SwDI animals was APOE. APOE is known to
bind to Ab and is involved in its deposition and transcystosis across
the blood brain barrier via its interaction with LDL-related protein
(LRP) [60], [61]. APOE expression has been manipulated in
various ways within the Tg-SwDI mouse model; though very little
data exists showing how the endogenous mouse APOE acts
naturally within the model. Expression of human APOE in the Tg-
SwDI mouse leads to a very different pattern of Ab deposition
than does endogenous APOE, such that human APOE reduces
microvascular accumulation of Ab [62]. Furthermore, when
APOE is blocked from interacting with Ab in Tg-SwDI mice, a
reduction in vascular fibrillar amyloid is observed [63]. We show
that the APOE co-localizes to Ab deposits closely associated with
cerebral vessels. Perivascular drainage of Ab is thought to play a
critical role in the clearance of Ab [64] and APOE has been shown
to co-localize to perivascular spaces as well as with astrocytic
endfeet in transgenic mouse models of amyloidosis [65]. Recent
work undertaken using specific antibodies to APOE suggests that
APOE might compete with clearance mechanisms for Ab at the
BBB, and suggests potential novel targets for therapeutic
intervention to reduce amyloidosis [66], [67].
We have also found a significant increase in the HTRA1 within
the vascular fractions of the Tg-SwDI mice at 9 months of age.
HTRA1 is a member of the trypsin family of serine proteases that
has properties similar to many heat shock proteins and typically
acts to prevent the aggregation of misfolded proteins [68]. It is
known to inhibit Tgfb signalling [69] and missense mutations are
associated with cerebral autosomal recessive arteriopathy with
subcortical infarcts and leukoencephalopathy [70]. HTRA1
cleaves multiple extracellular matrix (ECM) proteins including
fibronectin, collagen and aggrecan, which in turn could lead to
ECM remodelling [71]. HTRA1 has also been shown to degrade
proteins aggregates such as tau [72] and has been shown
previously to associate with Ab, and specifically vascular Ab
[73]. Further, when HTRA1 is inhibited in astrocyte cultures that
secrete Ab 1–40, there is a dose-dependent increase in the level of
Ab1-40, the major Ab species observed in CAA [73]. The
presence of HTRA1 in the vessels may indicate a potential
alternative clearance method of Ab or its involvement in ECM
remodelling around the blood vessels in reaction to accumulating
Ab.
Tg-SwDI animals also showed a very significant down-
regulation of proteins associated with RNA binding, processing
and transport [e.g. spliceosome proteins, heterogeneous nuclear
ribonucleoproteins (HNRNPs), TAR DNA-binding protein-43
(TDP-43)] at 9 months of age compared to 3 months of age. The
spliceosome is required for proper protein synthesis, as it is
involved in the formation of functional mRNA through excision of
introns and splicing of exons [74], [75]. Heterogeneous nuclear
ribonucleoproteins are involved in RNA binding and processing
[76], [77]. A large number of RNA-binding proteins have prion-
like domains (e.g. HNRNPA1, HNRNPAB, HNRNPA2B1, TDP-
43 [78]), some of these, such as TDP-43, have been implicated as
major disease proteins in neurodegenerative diseases such as
amyotrophic lateral sclerosis and frontotemporal lobar degenera-
tion and as secondary features of diseases like Alzheimer’s disease
and Parkinson’s disease [79].
Age has distinctly different effects on the proteomic profiles of
cerebral vessels from WT and Tg-SwDI animals. This is likely due
to the transgenic nature of the Tg-SwDI animals, which leads to
the vascular accumulation of Ab1-40. These differential effects
include changes in proteins from various cellular compartments
and with diverse cellular functions. Further investigation of these
proteins is warranted and may give greater insight to the
mechanisms behind age-related cerebrovascular dysfunction and
pathologies as well as provide novel therapeutic targets.
Supporting Information
Figure S1 Gene ontology analysis of proteins found to
be significantly different at p,0.01 within the WT cohort
were uploaded to WebGestalt Gene Set Analysis Toolkit
version 2.
(TIF)
Figure S2 A number of white matter-associated pro-
teins are significantly up-regulated in 9 month-old WT
and Tg-SwDI animals (**p,0.01; t-test). See Table 2 for
full list.
(TIF)
Figure S3 Gene ontology analysis of proteins found to
be significantly different at p,0.01 within the Tg-SwDI
cohort were uploaded to WebGestalt Gene Set Analysis
Toolkit version 2.
(TIF)
Table S1 Global list of all proteins quantified by at least
two peptides.
(XLS)
Table S2 Gene ontology analysis of proteins found to be
significantly different at p,0.01 within the WT cohort
were uploaded to WebGestalt Gene Set Analysis Toolkit
version 2.
(HTML)
Table S3 Gene ontology analysis of proteins found to be
significantly different at p,0.01 within the Tg-SwDI
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cohort were uploaded to WebGestalt Gene Set Analysis
Toolkit version 2.
(HTML)
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